Skip to Content

Risedronate Dosage

Applies to the following strength(s): 35 mg5 mg30 mg75 mg150 mg

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Osteoporosis

Treatment of Postmenopausal Osteoporosis:
Immediate release:
-5 mg orally once a day or
-35 mg orally once a week or
-75 mg orally on two consecutive days for a total of two tablets each month or
-150 mg orally once a month
Delayed release:
-35 mg orally once a week

Treatment to Increase Bone Mass in Men with Osteoporosis:
Immediate release:
-35 mg orally once a week

Treatment of Glucocorticoid-Induced Osteoporosis:
Immediate release:
-5 mg orally once a day

Comments:
-Refer to administration advice for details on how to take this drug.
-Reevaluate bisphosphonate therapy periodically.
-Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D.

Uses:
-Treatment to reduce the incidence of vertebral fractures and composite endpoint of nonvertebral osteoporosis-related fractures in postmenopausal women
-Treatment to increase bone mass in men with osteoporosis
-Treatment of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases

Usual Adult Dose for Prevention of Osteoporosis

Prevention of Postmenopausal Osteoporosis:
-5 mg orally once a day or
-35 mg orally once a week or
-75 mg orally on two consecutive days for a total of two tablets each month or
-150 mg orally once a month

Prevention of Glucocorticoid-Induced Osteoporosis:
-5 mg orally once a week

Comments:
-Refer to administration advice for details on how to take this drug.
-Reevaluate bisphosphonate therapy periodically.
-Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D.

Uses:
-Prevention of osteoporosis in postmenopausal women
-Prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases

Usual Adult Dose for Paget's Disease

-30 mg orally once a day for 2 months

Comments:
-Retreatment may be considered (following post-treatment observation of at least 2 months) if relapse occurs, or if treatment fails to normalize serum alkaline phosphatase.
-For retreatment, the dose and duration of therapy are the same as for initial treatment.
-There is no data available on more than 1 course of retreatment.

Use: Treatment of Paget's disease of bone in men and women

Renal Dose Adjustments

Mild to moderate renal dysfunction (CrCl 30 mL/min or more): No adjustment recommended.
Severe renal dysfunction (CrCl less than 30 mL/min): Not recommended.

Liver Dose Adjustments

No adjustment recommended.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-The delayed release tablets should be taken immediately following breakfast to avoid risk of abdominal pain.
-The immediate release tablets should be taken at least 30 minutes before the first food or drink of the day other than water.
-Food and other medications should not be taken for at least 30 minutes after taking the immediate release tablet.
-Tablets should be swallowed whole while in upright position, and with 8 to 6 ounces (immediate release) or 4 ounces (delayed release) of plain water; avoid laying down for 30 minutes after taking this drug.
-Tablets should not be chewed or sucked (potential for oropharyngeal ulceration), cut, or crushed.
-Supplemental calcium and vitamin D is recommended if dietary intake is inadequate.
-Calcium supplements, antacids, magnesium-based supplements or laxatives, iron preparations, vitamins, and any other medication should be taken at a different time of the day to avoid interference with the drug's absorption.

Missed Doses:
Immediate release:
If a dose of 35 mg once-a-week is missed:
-Take 1 tablet on the morning after remembering and return to take 1 tablet once-a-week as originally scheduled; two doses should not be taken on the same day.

If one or both tablets of 75 mg on two consecutive days per month dose are missed, and the next month's scheduled doses are more than 7 days away:
-If both tablets are missed, take one 75 mg tablet in the morning after remembering and then the other tablet on the next consecutive morning.
-If only one 75 mg tablet is missed, take the missed tablet in the morning after remembering; return to take one 75 mg tablet on two consecutive days per month as originally scheduled. No more than two 75 mg tablets should be taken within 7 days.

If one or both tablets of 75 mg on two consecutive days per month dose are missed, and the next month's scheduled doses are within 7 days:
-Wait until their next month's scheduled doses and then continue taking 75 mg tablet on two consecutive days per month as originally scheduled.

If the dose of 150 mg once-a-month is missed, and the next month's scheduled dose is more than 7 days away:
-Take the missed tablet in the morning after remembering and then return to take 150 mg once-a-month tablet as originally scheduled. No more than one 150 mg tablet should be taken within 7 days.

If the dose of 150 mg once-a-month is missed, and the next month's scheduled dose is within 7 days:
-Wait until their next month's scheduled dose and then continue taking 150 mg once-a-month tablet as originally scheduled.

Delayed release:
-If the once-weekly dose is missed, take one dose on the morning after remembering; two doses should not be taken on the same day.
-Resume the next dose on its regular schedule.

Limitations of Use:
-The optimal therapy duration of use has not been determined.
-The safety and effectiveness of this drug for the treatment of osteoporosis are based on three years duration.
-All patients on bisphosphonate therapy should reevaluated therapy on a periodic basis.
-Patients at low-risk for fracture should consider discontinuation of therapy after 3 to 5 years of use.
-If therapy is discontinued, reevaluate risk for fracture periodically.

Monitoring:
-Hematologic: Blood calcium levels
-Musculoskeletal: Bone, joint, or muscle pain

Patient advice:
-Patients should read the Medication Guide before starting therapy and each time the prescription is renewed.
-Instruct patients that the brands Atelvia and Actonel contain the same ingredient and should not be taken together.
-Patients should pay particular attention to the dosing instructions as clinical benefits may be compromised by failure to take the drug according to instructions.
-Consult a physician if symptoms of difficulty or pain upon swallowing, retrosternal pain or severe persistent or worsening heartburn develop before continuing taking this drug.

Hide